Clotic is a drug owned by Carwin Pharmaceutical Associates Llc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 26, 2042. Details of Clotic's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12246006 | Single-Dose Packaged Clotrimazole Liquid Composition |
May, 2042
(16 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Clotic's patents.
Latest Legal Activities on Clotic's Patents
Given below is the list of recent legal activities going on the following patents of Clotic.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eGrant Notification | 11 Mar, 2025 | US12246006 |
| Recordation of Patent eGrant | 11 Mar, 2025 | US12246006 |
| Patent eGrant Notification | 11 Mar, 2025 | US12246006 |
| Recordation of Patent Grant Mailed | 11 Mar, 2025 | US12246006 |
| Email Notification | 11 Mar, 2025 | US12246006 |
| Patent Issue Date Used in PTA Calculation | 11 Mar, 2025 | US12246006 |
| Email Notification | 19 Feb, 2025 | US12246006 |
| Issue Notification Mailed | 19 Feb, 2025 | US12246006 |
| Application Is Considered Ready for Issue | 05 Feb, 2025 | US12246006 |
| Dispatch to FDC | 05 Feb, 2025 | US12246006 |
FDA has granted several exclusivities to Clotic. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Clotic, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Clotic.
Exclusivity Information
Clotic holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2033. Details of Clotic's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 26, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 26, 2033 |
US patents provide insights into the exclusivity only within the United States, but
Clotic is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Clotic's family patents as well as insights into
ongoing legal events
on those patents.
Clotic's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Clotic's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 26, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Clotic Generic API suppliers:
Clotrimazole is the generic name for the brand Clotic. 12 different companies have already filed for the generic of Clotic, with Sun Pharma Canada having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Clotic's generic
About Clotic
Clotic is a drug owned by Carwin Pharmaceutical Associates Llc. Clotic uses Clotrimazole as an active ingredient. Clotic was launched by Carwin Assoc in 2025.
Approval Date:
Clotic was approved by FDA for market use on 26 September, 2025.
Active Ingredient:
Clotic uses Clotrimazole as the active ingredient. Check out other Drugs and Companies using Clotrimazole ingredient
Dosage:
Clotic is available in solution/drops form for otic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1% | SOLUTION/DROPS | Prescription | OTIC |